These studies demonstrate the potential of therapeutically promoting tumor immune surveillance in healthy, high-risk individuals by enhancing the baseline cytotoxic potential of the intestine by targeting and modulating FcRn binding to IgG (37). Here, FCGRT is linked to neoplasm.